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Abstract
The importance of immunoproteasomes to antigen presentation has been unclear because animals
totally lacking immunoproteasomes have not been previously developed. Here we show that
dendritic cells from mice lacking the three immunoproteasome catalytic subunits display defects
in presenting multiple major histocompatability (MHC) class I epitopes. During viral infection in
vivo, the presentation of a majority of MHC class I epitopes is markedly reduced in
immunoproteasome-deficient animals, while presentation of MHC class II peptides is unaffected.
By mass spectrometry the repertoire of MHC class I-presented peptides is ~50% different and
these differences are sufficient to stimulate robust transplant rejection of wild type cells in mutant
mice. These results indicate that immunoproteasomes play a much more important role in antigen
presentation than previously thought.
Proteasomes play a vital role in generating peptides for presentation on major
histocompatability (MHC) class I molecules1. Each proteasome consists of 14 structural
and 6 catalytic subunits (two each of the β1, β2 and β5 subunits)2. In addition to these three
catalytic subunits, three alternate catalytic subunits denoted as β1i (LMP2 or Psmb9), β2i
(MECL1 or Psmb10), and β5i (LMP7 or Psmb8) are constitutively expressed in a number of
hematopoietic cells and are induced in other cell types by interferon-γ (IFN-γ) 2,3. When
expressed, these alternate subunits preferentially incorporate into newly assembling
complexes to form immunoproteasomes3 and change the catalytic activities of these
complexes. Compared to the constitutive proteasomes, immunoproteasomes cleave more
rapidly after hydrophobic and basic amino acids and less rapidly after acidic ones4–6. Since
peptides with hydrophobic or sometimes basic C-termini preferentially bind to MHC class I
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molecules7, it has long been hypothesized that immunoproteasomes play a specialized role
in creating antigenic peptides. However, knock-out (KO) mice lacking individual
immunoproteasome catalytic subunits have relatively modest effects on antigen
presentation. For example,β 5i (LMP7) KO mice show a modest (~50%) decrease in MHC
class I surface expression8 and decreased or increased efficiency of presenting only a few
epitopes, while the majority of immunogenic peptides examined are presented normally8–15.
These analyses only examined the presentation of known epitopes and it is unknown
whether and how often immunoproteasome-deficient mice present different peptides than
wild-type (WT) mice.
To determine whether the modest phenotypes of these mice were due to some contribution
from the remaining immunoproteasome catalytic subunits, we created an
immunoproteasome triple KO mouse, lacking all the immune-subunits. Because the genes
for β1i (Psmb9) and β5i (Psmb8) are so close together on chromosome 17, making the
chance of generating a double knock by crossing β5i −/− with β1i −/− mice vanishingly small,
we chose to create a novel sequential KO of these two genes. We then bred the β1iβ5i double
KO mice to β2i −/− (MECL1 KO) mice to create the immunoproteasome triple KO (TKO)
animal. We found that the TKO mice had altered presentation of most of the epitopes we
tested, both in vitro and in vivo, and that these changes in antigen presentation were
sufficient to case TKO mice to reject WT cells.
Results
Generation of immunoproteasome triple KO mice
To generate the β1i and β5i double-deficient animals, we designed a sequential KO strategy
(Fig. 1a). First a LacZ-FRT-neo-FRT construct was fused in frame to the start codon (27 bp
downstream of the 5′ end of exon 1) of Psmb8 (which encodes β5i), removing the remainder
of exon 1 plus exons 2 through 5 by homologous recombination. The Neo gene was then
removed by FLPe activity in the bacteria. An alkaline phosphatase-loxP-neo-loxP construct
was then fused in frame to the start codon (22 bp from the 5′ end of exon 1) of Psmb9
(which encodes β1i, removing the remainder of exon 1 by homologous recombination. The
double KO was created on a 129 background, and mice were backcrossed 9 times onto the
C57BL/6J background. These mice were then bred to β2i KO16 mice to yield an
immunoproteasome triple KO. By the end of this process the resulting animals had been
backcrossed 10 generations onto the C57BL/6 background. The progeny of these animals
were analyzed for 110 SNPs spanning the genome and were found to be fully backcrossed to
C57BL/6.
The β1i and β5i subunits were undetectable by immunoblots in lysates or proteasome
preparations from the KO spleens, as expected (Fig. 1b,c). Also as expected the total amount
of proteasomes were the same in the TKO and WT spleens as assessed by immunoblotting
for an invariant alpha subunit in proteasome preparations (Fig. 1d). We also found that the
amount of ubiquitinated proteins were not different between the TKO and WT cells
(Supplementary Fig. 1).
Because the Psmb8 and Psmb9 genes flank the transporter 1, ATP-binding cassette, sub-
family B (MDR/TAP) gene (Tap1), we evaluated the expression of Tap1 in the β1iβ5i
double KO mice to see if it was affected. There was a partial (~50%) reduction in the
expression of Tap1 mRNA levels (Fig. 1b) and amount of protein (Fig. 1c). The amount of
Tap1 protein expressed in the KOs was similar to that of Tap1 +/− heterozygous mice (Fig.
1c) and therefore the latter mice were used as controls in some experiments.
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The TKO mice were viable, fertile and appeared healthy. The overall cellularity of their
thymuses and spleens were not different from wild type animals (Supplementary Fig. 2a,b).
However, there was a reduction of ~50% in the number of mature CD8 T cells in the
immunoproteasome-deficient thymus and spleen (Supplementary Fig. 2c,d), which was
similar to what had been observed in β1i single KO mice9. There was no reduction in their
number of B cells, which although different from that observed in β1i -deficient mice11,17,
was similar to the findings in β1iβ2i -double deficient mice17.
MHC class I expression in TKO mice
MHC class I molecules must bind peptides in order to be released from the endoplasmic
reticulum and traffic to the cell surface18. Consequently, the surface expression of MHC
class I molecules are a proxy for the overall supply of peptides for antigen presentation.
Therefore, we evaluated the surface expression of MHC class I molecules in the mutant
mice by analyzing cells stained with anti-MHC class I molecules by flow cytometry. Cells
lacking all three immunoproteasome catalytic subunits had only ~50% of MHC I surface
expression compared to WT cells (Fig. 2a,b). Both H2-Kb and H2-Db molecules were
similarly affected. There was a decrease in MHC class I surface expression on CD4+ and
CD8+ T cells in the blood, spleen, lymph nodes and thymus of TKO mice as well as on
lymph node B cells (B220+ cells) and splenic macrophages, dendritic cells (DC) and B cells
(CD11b+, CD11c+ and B220+ splenocytes, respectively). These findings were similar to
those with cells lacking only β5i, whereas cells lacking β1i or β2i expressed MHC class I
molecules at levels more similar to WT cells (Fig. 2c,d), as previously reported8,9,16. We
found no defect in MHC class I surface expression in Tap1+/− T or B cells, although we did
see a slight decrease in H2-Kb expression in splenic DC. Therefore, the reduction in MHC
surface expression on the TKO cells was not due to their modest reduction of Tap1.
To assay the relative stability of peptide-MHC I (pMHCI) complexes at the surface of TKO
cells, we treated WT and TKO splenocytes with brefeldin A (BFA) for 4 hours, and
monitored the MHC class I on the cell surface. We found no evidence of decreased stability
of pMHCI (H2-Kb or H2-Db) complexes in TKO animals (Supplementary Fig. 3). The
decreased surface expression, therefore, is most likely the result of decreased export of
mature pMHCI complexes as opposed to increased degradation of MHC I molecules
unstably bound to suboptimal peptides.
Defects in in vitro antigen presentation
Because the surface expression of MHC class I is reduced on a broad range of lymphoid and
myeloid cells, we inferred that there were defects in antigen processing that limited the
overall supply of peptides to MHC class I molecules. To evaluate antigen presentation more
directly, we examined the presentation of a number of well-characterized epitopes by these
cells. We used DC for many of these assays because they have been shown to constitutively
express the immunoproteasome catalytic subunits19,20.
To examine presentation of the male H-Y antigen-derived peptide antigen Smcy 738–746,
we measured proliferation of Smcy-specific purified H-Y TCR transgenic T -cells21,22 in
response to male C57BL/6 and TKO bone marrow-derived DC (BMDCs). The proliferation
of H-Y T-cells cocultured with male (antigen bearing) TKO dendritic cells was extremely
low, and was in fact similar to that of H-Y T-cells cocultured with DCs from C57BL/6
females, which lack the Smcy antigen (Fig. 3a). In contrast, the presentation of the Smcy
epitope by DCs derived from the three immunoproteasome single KO or Tap1+/− mice was
similar to that seen with WT DCs.
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We also measured the presentation of the male antigen Uty 246–254 to the T-T hybridoma
11p9z23,24. TKO DCs also had severely impaired presentation of this epitope (Fig. 3b).
Consistent with previously published results13, we found that the β5i single KO also showed
defective presentation in this assay.
To further assess potential deficiencies in antigen processing and presentation by TKO cells
we employed two other systems. First, we measured presentation of influenza peptide
NP366 by influenza-infected BMDC to the 12.64-CD8αβ-LUC hybridoma (a derivative of
12.6425 expressing firefly luciferase under the control of the NFAT promoter) and found
that TKO BMDC presented this epitope extremely poorly, especially at early time points
(Fig. 3c). Previous reports have found no effect of β2i deficiency or β5i -β2i double
deficiency14 on NP366 presentation, but reports have differed as to whether there is an
effect of β1i single-deficiency on NP366 presentation (varying from no effect to a partial
reduction)9,10,14. Second, we measured presentation of the OVA257–264 epitope (SIINFEKL)
by splenocytes from OVA transgenic and TKO OVA trangenic mice to the RF33.70-LUC
hybridoma (a derivative of RF33.7026 expressing firefly luciferase under the control of the
NFAT promoter), and found that the TKO spleens presented less of this epitope than WT
cells (Fig. 3d). In contrast, we found that cells that were infected with recombinant vaccinia
(rVV) expressing a minigene that did not require cleavage, presentation of SIINFEKL was
not reduced in TKO cells (Fig. 3e). In contrast previous studies have shown that β1i KO9,
β5i KO12 and β5i -β2i double KO animals15 present this antigen normally. Overall these
analyses revealed that cells lacking immunoproteasomes had a broad defect in antigen
presentation that affected all the four epitopes examined.
Decreased presentation of LCMV epitopes in vivo
To measure antigen presentation in vivo, we transferred WT P14 TCR transgenic T cells
(specific for GP33 viral epitopes) into lymphochoriomeningitis virus (LCMV)-infected WT
and TKO mice and assayed their stimulation. Two days after infection with LCMV, WT and
TKO mice were injected with naïve BFA-treated P14 lymphocytes (and in addition BFA to
maintain the secretion block). Splenocytes were then harvested 4 hours later from these
animals, and the production of tumor necrosis factor α (TNFα) and IFN-γ by the P14 cells
was detected by intracellular cytokine staining and quantified by flow cytometry. This
protocol allowed us to quantify activation of the TCR transgenic T cells by their cognate
antigen within the first 4 hr of stimulation by antigen-presenting cells in vivo. Of note, there
was no relative loss of the P14 T cells transferred into TKO mice, because the time point we
analyzed was much too early for immune-based rejection to occur (an issue discussed
below). Both TNFα and IFN-γ production by P14 cells were significantly reduced in TKO
mice compared to WT controls (Fig. 4a,b), consistent with decreased presentation of the
GP33 epitope in TKO hosts.
To evaluate the role of immunoproteasomes in presentation of other LCMV antigens in
vivo, we transferred LCMV-immune WT splenocytes into WT and TKO mice and 24 hours
later infected the animals with LCMV. To prevent rejection of the adoptively transferred
cells, we depleted the host T cells with anti-Thy1.2 antibody, and, as expected, there was no
relative loss of the transferred cells in TKO hosts (see below). We then harvested
splenocytes from WT and TKO hosts at 5.5 days post infection and quantified the activation
of different peptide specific T cells by in vitro re-stimulation and intracellular cytokine
staining. CD8 T cell responses to GP33 were reduced, confirming the results obtained with
the P14 transgenic T cells, which recognize this peptide. Moreover, responses to most other
epitopes in vivo were significantly reduced, consistent with a defect in processing and
presentation of a broad array of epitopes in the TKO mice (Fig. 4c). Although it is formally
possible that the responses of WT T cells in TKO animals could be affected by host factors,
such as regulatory T cells, the decreased responses of the transferred T cells in TKO animals
Kincaid et al. Page 4













most likely reflect reduced antigen presentation, especially because the host was depleted of
T cells. On the other hand it should be noted that since the responding T cells are WT, this
experimental design excludes any possible defect in the proliferative responses of
immunoproteasome-deficient T cells (although we have not seen any such defects in
responses of TKO T cells to antigens, Supplementary Fig. 4, or homeostatic proliferation in
two experiments in which these cells were transferred to lymphopenic RAG-deficient hosts,
not shown) or in their repertoire.
Responses to three peptides, NP396, GP276 and GP92, were not reduced, and the response
to NP205 was reduced, but did not reach the level of statistical significance (Fig. 4c and
inset). In the case of the NP396 epitope, it is possible that our assay system could miss a
reduction in its presentation if the number of peptide-MHC complexes are in excess of what
is needed to maximally stimulate the T cells; this might occur in a viral infection because the
NP396 peptide has a very high binding affinity to H2-Db27. The LCMV GP276 epitope, on
the other hand, seems to be produced better by the TKO animals. This epitope has been
previously shown to be destroyed by β1i in vitro 28, so its increased presentation may reflect
decreased destruction of this epitope in TKO APC.
Because responses to GP33 and GP34 were decreased in TKO mice while the responses to
NP396 were not significantly different, the immunodominance hierarchy was dramatically
altered in the TKO mice. The defects in T cell responses in TKO mice are significantly more
widespread than what has been reported in single KO animals. β1i KO11 and β2i KO16 mice
have been shown to have decreased CD8 T-cell responses to LCMV GP276 and NP205 but
normal responses to NP396, GP33 and several other LCMV epitopes. β5i KO mice were
reported to have normal responses to all LCMV peptides11.
We found no defects in CD4 T cell responses to the MHC class II epitopes GP61 and NP309
(Fig. 4d) in these mice, although the NP309 responses were very close to background. We
also looked at CD4 T cell responses in unmanipulated WT and TKO mice infected with
LCMV and found that the responses to these epitopes were not decreased in TKO mice
(Supplementary Fig. 4), and that the NP309 were easier to detect above the background. The
normal CD4 T cells responses in LCMV infected TKO mice suggest that neither APC nor T
cells are globally affected in these mice, but that the defects are specific to MHC class I
antigen presentation.
TKO mice reject WT splenocytes
The finding that immunoproteasome-deficient APC have marked differences in the
presentation of a majority of tested T cell epitopes raised the possibility that these mutant
cells might not just have quantitative difference in antigen presentation but also be
generating a different set of peptides than WT cells. If this were the case TKO T cells would
not be tolerant to many of the self peptides presented on immunoproteasome-expressing WT
cells and would be stimulated to reject these cells. To test this hypothesis, we injected TKO
mice with a mixture of carboxyfluorescein diacetate succinimidyl ester (CFSE)-labeled WT
and TKO splenocytes and then monitored the proportion of WT to TKO splenocytes in the
blood of host animals over 11 to 12 days. On ~day 4 after transfer the WT cells
progressively disappeared in TKO hosts and were profoundly depleted by 11 days post
injection (Fig. 5a). We also performed these experiments with the 3 single
immunoproteasome KO strains, and found that WT cells were also rejected by the single KO
animals, albeit with much slower kinetics (Fig. 5a,b). These results suggest that WT
splenocytes present a markedly different, repertoire of peptides than those found in either
the thymus or periphery of TKO animals, resulting in recognition of this
immunoproteasome-derived repertoire as foreign epitopes. Moreover, the data are consistent
with a defect in the generation of presented peptides in TKO mice that is substantially
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greater than in any of the single immunoproteasome subunit-deficient mice. To confirm that
the recognition and rejection of the WT cells was CD8 T cell mediated, we depleted host T
cells using an anti-Thy1.2 specific antibody. TKO animals whose T cells had been depleted
did not reject WT splenocytes (Fig. 5c).
In reciprocal experiments we injected a mixture of CFSE-labeled WT and TKO splenocytes
into WT mice. In contrast to the results observed in the TKO host, both cell populations
survived in WT hosts (Supplementary Fig. 5). This difference between the WT hosts and
TKO hosts is not surprising. The TKO host has never seen any of the unique peptides
generated by immunoproteasomes and therefore would not be tolerant to them. In contrast,
WT mice express constitutive proteasomes and immunoproteasomes, so the animals would
be expected to be tolerant to the peptides generated by both types of proteolytic complex.
Changes in MHC I peptide repertoire
Having found a difference in the peptides presented by WT and TKO splenocytes as
measured by immune-based rejection, we wanted to look in more detail at the peptides
bound to MHC class I in the two strains. To identify naturally processed peptides, we
isolated H2-Kb or H2-Db molecules from splenocytes, eluted the peptides, fractionated them
by high pressure liquid chromatography and analyzed the results by mass spectrometry.
Because TKO splenocytes present approximately half as much MHC class I on the cell
surface as WT splenocytes, we needed to use more TKO spleens to achieve similar yields of
peptides from the two strains. In the raw (unvalidated) data from two independent
experiments, we identified 398 distinct peptide sequences in the material extracted from WT
H2-Kb (81% of which were not found in TKO),. 581 sequences from WT H2-Db (78% not
found in TKO), 331 sequences from TKO H2-Kb (77% not found in WT) and 570 sequences
from TKO H2-Db (78% not found in WT). This data represents unvalidated masses and
based on our previous experience includes a large number of erroneously assigned
sequences. Valid peptide sequences were identified with high confidence using an initial
search with Spectrum Mill algorithm followed by expert manual spectral validation. We
identified a total of 270 WT and 297 TKO validated peptide sequences. While some
validated peptides were shared by the two strains, we identified a large proportion of
peptides that were found only in one strain (Fig. 6 and Supplementary Tables 1, 2, 3 and 4).
Although WT mice can express both the constitutive and immune proteolytic subunits, WT
splenocytes express only minor amounts of the constitutive subunits29, so the peptides
unique to TKO are presumably the products of constitutive proteasomes. The mass
spectrometry technique that we used did not allow us to determine the relative frequency of
each peptide in each strain, so our data likely underestimate the differences between the
peptide repertoires of the two strains. The results show that despite the transport-selectivity
of Tap1 and the binding-selectivity of the MHC I molecules themselves, the differences in
the biochemical activities of the proteasome and immunoproteasome subunits results in
different peptides bound to MHC class I.
Discussion
Our results with TKO mice reveal the vital role of immunoproteasomes in creating peptides
for MHC class I antigen presentation. The profound defects in antigen presentation that we
find in the triple KO APCs, both in vivo and in vitro, are qualitatively and quantitatively
much broader than the previously described defects in any of the β1i, β2i or β5i single KO
animals and are far greater than the sum of the defects in single knock out animals. The
findings suggest that functional overlap between the subunits has masked the true
importance of immunoproteasomes.
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Of the eleven MHC class I presented antigens we examined, we found clear alterations in
nine (i.e. 82%) – eight of which had reduced presentation. In the case of the Smcy antigen,
expressed on male cells, there was a significant reduction in presentation by TKO cells even
though none of the single KO mice showed a defect. In the case of LCMV GP33 and
GP118, there were defects in the response to these epitopes, where none have been
previously described with single KO animals11,16. Similarly there was a partial defect in
OVA 257–264 presentation not previously seen in single KOs9,12,15 and also a much more
marked defect in the presentation of Influenza NP366–3749,10,14. We believe, therefore, that
data from single KO animals have substantially underestimated the contribution of the
immunoproteasomes to generating peptides for MHC class I antigen presentation.
Our finding that many epitopes are presented poorly by cells that completely lack
immunoproteasomes are consistent with inefficient generation of optimal peptides by
constitutive proteasomes. Presumably this defect in generating peptides accounts for the
approximately 50% decrease in MHC class I surface expression in the TKO mice. Although
this decrease in MHC class I is similar to that in β5i single KO animals (our data here and8),
the peptides that the two strains present are almost certainly not identical. Compared to
β5i.−/− animals, TKO mice present many peptides more poorly and more rapidly reject WT
cells. The profound difference in Smcy presentation between β5i KO DCs (which present the
antigen normally) and TKO DCs (which present the antigen very poorly) despite the
quantitatively similar MHC class I surface expression, suggests that the decreased
presentation in the TKO cells cannot be due to the decrease in overall MHC molecules but
rather are a result of a poor supply of peptides.
In the absence of immunoproteasomes, there were changes in antigen presentation in vitro in
dendritic cells and, importantly, also in vivo. During LCMV infection, we observe changes
that affect the magnitude of T cell responses, generally substantially reducing responses.
GP276, the one epitope for which we found better presentation by TKO cells, has been
previously shown to be destroyed by β1i in vitro 28. The fact that these changes in antigen
presentation effect CD8 T cell responses in TKO animals (to the point of altering the
immunodominance hierarchy) is impressive in the face of an immunogen as robust as
LCMV.
The defects that we observed in vivo selectively affect the MHC class I antigen processing
pathway. Loss of immunoproteasomes decreased responses to epitopes from several protein
antigens but not from a minigene whose product does not require cleavage for presentation.
Moreover, we find no defect in CD4 numbers in response to MHC class II epitopes in vivo,
indicating that APC function is not globally decreased. We also conclude that the decreased
CD8 T cell responses in TKO mice are not due to pleiotropic effects on T cells, but to
antigen presentation defects, since the decreases are found in WT T cells transferred into
TKO hosts. Moreover, we also find no defect in CD4 numbers or responses in naïve or
LCMV-infected animals.
In addition to the differences we observed in the presentation of 9 of 11 immunogenic
epitopes, we found that the peptide repertoire of TKO animals is qualitatively substantially
different from WT or any single KO, as evidenced by the robust rejection of WT cells by
TKO animals. This is particularly impressive because differences in minor
histocompatibility antigens, which are presented peptides that differ between strains due to
allelic polymorphisms, stimulate rejection much more slowly. It should be noted that
rejection of the WT cells is unlikely to be due to minor histocompatibility differences,
because the TKO animals were fully backcrossed. In addition, such histocompatibility
differences would be expected to elicit bidirectional responses between the strains, but we
found no rejection of TKO cells by WT animals. Instead, this ‘one way’ rejection suggests
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that cells in WT animals present a substantially different set of peptides than those found in
TKO animals, containing epitopes generated by both immunoproteasomes and constitutive
ones. Consistent with these results and quite remarkably, comparison of the peptides eluted
from matched samples of MHC class I molecules on wild type versus TKO splenocytes
revealed that only about one half of the peptides from both Db and Kb were shared between
the two strains. This is likely an underestimate because the mass spectrometry analysis
detects the presence of abundant peptides but not their precise amount. Therefore, even
among the peptides that were in common between the WT and TKO mice there are likely
quantitative differences, as we found such differences in the presentation of the majority
(82%) of immunogenic epitopes in quantitative assays. When the peptides we identified as
unique to immunoproteasome-deficient mice are compared against a larger data set of BL6-
presented peptides from the literature, 75–80% are still only present in the TKO pools. The
20–25% of additional ‘shared’ peptides could have been generated by constitutive
proteasomes in previous WT preparations and/or by the detection of lower abundance
peptides in previous analyses.
Taken together, these results demonstrate the importance of immunoproteasomes in
generating peptides for MHC class I antigen presentation, a contribution that has been
previously substantially underestimated. A potentially important implication of our findings
is that under non-inflammatory conditions the peptides presented by DC, which
constitutively express immunoproteasomes, will be substantially different from the ones
displayed on parenchymal cells, which contain only constitutive proteasomes. Therefore, T
cell responses stimulated by DC may not optimally recognize parenchymal cells until
immunoproteasomes are induced in the latter by interferon. This may reduce the
effectiveness of CD8 T cell immunity in situations where IFN-γ is not produced. Similarly,
this could help pathogenic cells that fail to respond to IFN-γ and/or express
immunoproteasomes, such as some tumors or cells infected with viruses that inhibit IFN-γ
responses, evade immune responses.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Fig. 1. β1i and β5i double KO mice
(a) Exons targeted for the sequential KO of both Psmb9 and Psmb8 to generate double
deficient mice. β1i and β5i proteins are not detected in spleen cell lysates (b) or proteasomes
purified from splenocytes (c) (equivalent protein loaded in each lane). (d) The amount of
proteasomes in WT and TKO spleens is similar, as measured by alpha subunits in serial
dilutions of proteasome pellets from equal numbers of spleens. (e) Normalized TAP1
mRNA expression in WT and β5iβ1i double KO splenocytes, determined by RT-qPCR. Bar
indicates mean +/− SD of 5 animals for each strain. Asterisk indicates P < 0.05 (Two-tailed,
unpaired t-test).(f) Immunoblotting of splenocyte whole cell lysates from the indicated
strains, using anti-TAP1 antibody (equivalent protein loaded in each lane).
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Fig. 2. MHC class I surface expression in TKO and immunoproteasome single KO animals
Blood or organs were harvested from mice of the indicated strains (a) H2-Kb and (b) H2-Db
surface expression on cells from WT and TKO mice. In both cases, MHC class I surface
expression in TKO mice are significantly reduced compared to WT mice. (Two-way
ANOVA, P < 0.0001, n between 3 and 33 depending on the strain and tissue). Bar graphs
indicate mean +/− SD. H2-Kb surface expression on splenocytes gated on B220+ (B cells)
(c) or CD11c (dendritic cells) (d). Scatter plots indicate individual animals with mean +/−
SD indicated. Asterisks indicate a significant difference from WT (P < 0.05, One-way
ANOVA followed by Dunnet’s Multiple Comparison Test, n of 3 to 6 for each strain). All
results are normalized to the average of WT controls in each experiment.
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Fig. 3. Presentation of H-Y antigens, influenza and OVA by immunoproteasome triple KO
dendritic cells is decreased
(a) BMDC from the indicated mouse strains (male unless otherwise indicated) were serially
diluted and combined with 3×104 purified HY CD8+ T cells per well. After 3 d of co-
incubation, 3H-Thymidine was added and cells were harvested 5 h later. Representative of 4
experiments. (b) Uty antigen presentation in male BMDC of the indicated strains was
assayed using 11p9z hybridoma cells. Secreted IL-2 was measured using the CTLL
bioassay. Representative of 3 experiments. (c) After a 4 h influenza infection NP366 antigen
presentation by infected WT and TKO BMDC was assayed by co-incubating with 12.64-
CD8αβ-LUC hybridoma for 12 h. Relative luciferase units (RLU) are shown.
Representative of 4 experiments. (d) SIINFEKL antigen presentation by irradiated
splenocytes from WT, OVA transgenic or TKO OVA transgenic animals was assayed using
RF33.70-LUC hybridoma cells. Representative of 2 experiments. (e) WT and TKO BMDC
were infected with rVV-SIINFEKL and fixed after 2 h. SIINFEKL presentation was assayed
using RF33.70-LUC hybridoma cells. Representative of 2 experiments. For panels A
through D, responses to TKO cells were significantly different from responses to WT cells
(Two-way ANOVA, P < 0.0001). Responses were not significantly different between WT
and TKO cells in panel E. Error bars indicate S.D. of triplicate values.
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Fig. 4. Altered T cell responses in LCMV-infected TKO mice
(a,b)Two days post LCMV infection, WT and TKO animals were injected with BFA and
BFA-treated P14 Tg splenocytes. Spleens were harvested 4 hours later, stained (surface and
intracellular) and analyzed by flow cytometry. Representative of 3 experiments. (c,d)To
prevent rejection of adoptively transferred cells, host T cells were depleted in WT
Thy1.1+Thy1.2+ and TKO Thy1.1+Thy1.2+ mice using anti-Thy1.2. 3×107 LCMV-immune
WT Thy1.1 splenocytes were injected i.v. one day before LCMV infection. 5.5 days post-
infection, animals were sacrificed and spleens were harvested. Cells analyzed by in vitro
restimulation followed by surface and intracellular cytokine staining. Mean and standard
deviation of 3 animals of each strain, representative of two experiments. Inset shows low
abundance CD8 T-cell responses, enlarged from (c). Asterisk indicated P<0.05, by two-
tailed, unpaired t-test.
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Fig. 5. TKO hosts reject WT splenocytes
(a) Mice of the indicated strain were injected with WT and KO cells differentially labeled
with CFSE. Mice were bled at the indicated times, and the selective killing of WT cells was
assessed. Mean ±SD from: TKO, 14 mice, 3 experiments; β1i, 10 mice, 3 experiments; β5i, 5
mice, 1 experiment; β2i, 7 mice, 2 experiments. (b) Killing of WT splenocytes by single and
TKO mice at day 7 or 8 (One way ANOVA, with Dunnett’s Multiple Comparison test,
asterisk indicates P < 0.05). (c) Similar to (a) except the TKO host T cells were depleted
with anti-Thy1.2 antibody (30H12) before injection of WT splenocytes.
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Fig. 6. Distinct peptides presented on WT and TKO splenocytes
Comparison of peptides identified by tandem mass spectrometry (MS/MS) in WT and TKO
animals. pMHCI complexes were isolated with anti H2-Db (a) or anti H2-Kb (b) antibodies.
Numbers indicate the number of identified peptides that were unique to WT splenocytes,
unique to TKO splenocytes or shared by both.
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